Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Looking to add some growth to your portfolio? Here are some high-growth names that deserve a second look.

We created this list by first screening the drugmakers industry of the healthcare sector for high-growth stocks, with 5-year projected EPS growth above 15%.

We then screened for those with bullish sentiment from institutional investors, with significant net institutional purchases over the last quarter representing at least 5% of share float. This indicates that institutional investors such as hedge fund managers and mutual fund managers expect these names to outperform in the future.

For an interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research.

Tool provided by Kapitall. More investing ideas on Kapitall Wire.

Do you think these companies will meet their high-growth prospects? Use this list as a starting point for your own analysis.

List sorted by net institutional purchases as a percent of share float.

1. Horizon Pharma, Inc. (NASDAQ:HZNP): Develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. Market cap at $174.23M, most recent closing price at $4.98. 5-year projected EPS growth at 20.00%. Net institutional purchases in the current quarter at 7.4M shares, which represents about 29.85% of the company's float of 24.79M shares.

2. POZEN Inc. (NASDAQ:POZN): Develops products for the treatment of acute and chronic pain, and other pain-related conditions in the United States. Market cap at $192.68M, most recent closing price at $6.38. 5-year projected EPS growth at 30.00%. Net institutional purchases in the current quarter at 2.5M shares, which represents about 11.75% of the company's float of 21.28M shares.

3. MAP Pharmaceuticals, Inc. (NASDAQ:MAPP): Focuses on the development and commercialization of inhalation therapies for patients suffering from migraine. Market cap at $414.29M, most recent closing price at $13.72. 5-year projected EPS growth at 49.00%. Net institutional purchases in the current quarter at 2.1M shares, which represents about 8.17% of the company's float of 25.69M shares.

*Institutional data sourced from Fidelity, all other data sourced from Finviz.

Source: Hedge Funds Love These 3 High-Growth Drugmakers